A normal life expectancy, despite HIV infection?

AIDS

Volumn 24, Issue 10, 2010, Pages 1583-1584

  Hill, Andrew ^a   Pozniak, Anton ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

AIDS; CD4 cell count; HIV; life expectancy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; NEVIRAPINE; RITONAVIR; THYMIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER INCIDENCE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS; DISEASE COURSE; EXERCISE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INCIDENCE; LIFE EXPECTANCY; LIFESTYLE; LIVER DISEASE; LIVER TOXICITY; MORTALITY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; SMOKING; STEVENS JOHNSON SYNDROME; SURVIVAL RATE;

CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; LIFE EXPECTANCY;

EID: 77953914631     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ac7d4     Document Type: Note

References (15)

1. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
2. Lohse N, Hansen A, Pedersen G, Kronborg G, Gerstoft J, Sorensen H, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
3. The Data Collection on Adverse Events of Anti-HIV drugs (DAD) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the DAD study. AIDS 2010; 24:1537-1548.
4. Sabin CA. Early antiretroviral therapy: the role of cohorts. Curr Opin HIV AIDS 2009; 4:200-205.
5. Olsen C, Gatell J, Ledergerber B, Katlama C, Friis-Moller N, Weber J, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS 2005; 19:319-330.
6. Philips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al. UK Collaborative HIV Cohort (CHIC) Study. Rate of AIDS diseases or death in HIV-infected antiretroviral ther-apy-näive individuals with high CD4 cell count. AIDS 2007; 21: 1717-1721.
7. Kaufmann G, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years. Ann Intern Med 2003; 163:2187-2195.
8. Mocroft A, Phillips A, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413.
9. Battegay M, Fehr J, Fluckige U, Elzi L. Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 2008; 62:41-44.
10. Kitahata MM, GangeS,Abraham A, Merriman B, SaagM, Justice A, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
11. When to Start Consortium Sterne JA, May M, Costagliola D, de Wolf F, Philips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1 infected patients: a collaborative analysis of 18 cohort studies. Lancet 2009; 373: 1352-1363.
12. Lundgren J, Reiss P, Worm S, Weber R, El-Sadr W, De Wit F, et al. Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI and NRTI classes: the DAD study [abstract 44LB]. 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 2009.
13. Fagot J, Mockenhaupt M, Bouwes-Bavinck J, Naldi L, Viboud C, Roujeau J, and the EuroSCAR study group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necroly-sis. AIDS 2001; 15:1843-1848.
14. Hughes M. Initial treatmentof HIV infection: randomized trials with clinical end points are still needed. J Inf Dis 2006; 194:542-544.
15. The Antiretroviral Cohort Collaboration. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Inf Dis 2006; 194:612-622.